Free tool
FAERS Monitor: Cleviprex
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022156 or its brand name (Cleviprex, Clevidipine). Reports on generic versions are filed under their own applications.
Reports
367
Serious
226
62% of reports
Hospitalization
52
Death reported
23
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective36
- hypotension30
- hypoxia27
- ventilation perfusion mismatch25
- oxygen saturation decreased18
- tachycardia17
- atrial fibrillation15
- bradycardia13
- extravasation13
- blood pressure inadequately controlled11
- off label use11
- infusion site extravasation10
- blood triglycerides increased9
- drug administration error9
- no adverse event8
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2007 | 1 |
| 2009 | 77 |
| 2010 | 18 |
| 2011 | 12 |
| 2012 | 5 |
| 2013 | 3 |
| 2014 | 17 |
| 2015 | 12 |
| 2016 | 25 |
| 2017 | 7 |
| 2018 | 21 |
| 2019 | 25 |
| 2020 | 29 |
| 2021 | 16 |
| 2022 | 24 |
| 2023 | 27 |
| 2024 | 20 |
| 2025 | 17 |
| 2026 | 11 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,792 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| ventilation perfusion mismatchSignal | 25 | 5602.3 | 3763.8 | 122,500 |
| extravasationSignal | 13 | 181.9 | 106.5 | 2,154 |
| blood pressure inadequately controlledSignal | 11 | 105.0 | 58.6 | 1,030 |
| infusion site extravasationSignal | 10 | 92.2 | 50.0 | 812 |
| hypoxiaSignal | 27 | 44.0 | 30.6 | 1,092 |
| blood triglycerides increasedSignal | 9 | 29.2 | 15.3 | 218 |
| oxygen saturation decreasedSignal | 18 | 18.4 | 11.7 | 279 |
| drug administration errorSignal | 9 | 16.8 | 8.8 | 119 |
| bradycardiaSignal | 13 | 14.1 | 8.2 | 145 |
| tachycardiaSignal | 17 | 11.0 | 6.9 | 145 |
| atrial fibrillationSignal | 15 | 8.8 | 5.4 | 97 |
| hypotensionSignal | 30 | 8.6 | 6.1 | 195 |
| no adverse eventSignal | 8 | 2.5 | 1.3 | 6 |
| drug ineffective | 36 | 1.6 | 1.1 | 7 |
| off label use | 11 | 0.7 | 0.4 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.